Guardant Health Asia, Middle East & Africa (AMEA)

Genomic testing can help advanced stage cancer patients find treatment options. At Guardant Health AMEA, we are committed to providing a high-quality and accessible test option to patients in Asia, Middle East and Africa.

We work with leading health service providers to help give you and your doctors the comprehensive genomic profiling information you need. For questions about how to access Guardant360®, please contact our local partner.

If you have any queries, send us an email at: clientservices@guardantamea.com.

GUARDANT™

How Do You Order Guardant360®?

1.

Ask your physician about placing an order for the Guardant360® kit.

2.

Two tubes of blood (10ml each) will be drawn.

3.

The blood specimens will be sent to Guardant Health's laboratory in the US.

4.

Upon receipt in the US laboratory, the test report will be ready in approximately seven days.

5.

The test report will be sent to your physician.

6.

Your physician can use the information to select the most appropriate treatment.

Guardant360® Sample Test Result

(For illustrative purposes only)

Doe, James (A37111)
Patient MRN: 2345678 | DOB: MAR-21-1970 | Gender: Male
Diagnosis: Non-small Cell Lung Cancer | Test Number 1

GUARDANT360
Therapy Finder Page

REPORTING
Final Report Date: JUL-02-2019
Receipt Date: JUN-21-2019
Collection Date: JUN-19-2019
Specimen: Blood
Status: Final

PHYSICIAN
Mary Smith
Account: Pleasantville Oncology
Address: 1234 Main Street,
Nashville, TN 37011 United States
Ph: 111.111.1111 | Fax: *222.222.2222*
Additional Recipient: James Brown

Complete Tumor Response Map on page 2

Summary of Somatic Alterations & Associated Treatment Options

KEY: Approved in indication | Approved in other indication | Lack of response

Alteration	% cfDNA or Amplification	Associated FDA-approved therapies	Clinical trial availability (see page 3)
EGFR L858R	0.5%	Erlotinib, Gefitinib, Afatinib	Yes
EGFR Amplification	Low (+)	Necitumumab	Yes
TP53 R156P	1.2%	None	Yes

Variants of Uncertain Significance
EGFR L392M (9.2%)
The functional consequences and clinical significance of alterations are unknown. Relevance of therapies targeting these alterations is uncertain.

Synonymous Alterations
MET A1357A (0.2%)
This sequence change does not alter the amino acid at this position and is unlikely to be a therapeutic target. Clinical correlation is advised.

We evaluated 74 genes, including the following guideline-recommended genes for NSCLC:

EGFR (T790M and others)	*ALK*	*ROS1*	*BRAF*	*MET*	*ERBB2* (HER2)	*RET*

GUARDANT™

Helping advanced cancer patients get the right treatment with a simple blood draw

SAMPLE RECEIPT TO RESULTS 7 DAYS

scan for more info

GUARDANT360®
Test. Take Action.

Patient Brochure